Sam, Author at Cyclotek

Cyclotek and Duchembio announce APAC extension of the license agreement for [18F]FP-CIT for the diagnosis of neurodegenerative disorders

Posted on: 25 September 2025Clinical,Company,Latest News

Building on Cyclotek’s original 2017 agreement with Duchembio Co. Ltd., Cyclotek now holds
read More
Cyclotek Awarded CRC-P Round 16 Grant to Advance Nanobody-Based Theranostic Platform for Cancer

Posted on: 03 September 2025Clinical,Company,Latest News,Research

Cyclotek, Australia’s leading radiopharmaceutical CDMO, is proud to announce its successful
read More
Cyclotek Enables First in Human Company-Sponsored Trial with Terbium-161 Radiopharmaceutical in Australia

Posted on: 03 July 2025Clinical,Latest News,Research

Cyclotek is excited to announce a contract development and manufacturing agreement with Radio
read More
Cyclotek Expands Radiopharmaceutical Capacity in Queensland: A New Era for Imaging and Therapy Providers

Posted on: 27 February 2025Company,Latest News

Cyclotek is excited to announce a significant expansion of our radiopharmaceutical manufactur
read More
Cyclotek and the University of Melbourne sign Strategic Partnership Agreement

Posted on: 30 January 2025Company,Latest News,Research

Radiopharmaceutical manufacturer Cyclotek and the University of Melbourne have signed
read More
Cyclotek Expands Radiopharmaceutical Manufacturing Capacity in Auckland

Posted on: 16 December 2024Company,Latest News

Cyclotek, innovative leader in the field of radiopharmaceutical manufacturing for over 24 yea
read More

© 2025 Cyclotek. All rights reserved

[contact-form-7 id=”714″ title=”Update Form”]